Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
Publication year range
1.
J Natl Cancer Inst ; 70(1): 45-8, 1983 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-6571920

RESUMEN

In vitro cytogenetic studies of amosite, chrysotile, and crocidolite asbestos have shown that these fibers may induce chromosome abnormalities and an elevated sister chromatid exchange (SCE) rate in mammalian cells. Twenty-five asbestos insulators (6 with radiographic asbestosis) were compared to 14 controls frequency matched for age and were found to have a marginally increased SCE rate in circulating lymphocytes with increasing years of exposure (P= 0.057). There was a significant association between SCE rate and smoking (P=0.002) after controlling for years of asbestos exposure and age. Smoking asbestos insulators had the highest SCE rate. Sister chromatid exchanges in chromosomes of group A, i.e., the group with the longest chromosomes, were significantly associated with asbestos exposure and cigarette smoking, with an interaction between the two.


Asunto(s)
Amianto/efectos adversos , Asbestosis/genética , Intercambio Genético/efectos de los fármacos , Intercambio de Cromátides Hermanas/efectos de los fármacos , Células Cultivadas , Humanos , Linfocitos/fisiología , Fumar
2.
Acta Anaesthesiol Sin ; 35(1): 25-32, 1997 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-9212478

RESUMEN

BACKGROUND: Controlled-release morphine (MST) given twice daily provides a simpler and more convenient treatment regimen than 4-hourly opioid administration for the control of cancer pain. Recently, a new formulation of transdermal fentanyl (TDF) has been developed which provides a new route for the treatment of cancer pain. The present study was designed to compare the analgesic efficacy, safety and adverse effects of MST and TDF in the management of chronic cancer pain. METHODS: In this open, comparative and randomized study, patients were treated with oral morphine hydrochloride immediate-release (MHIR) in the stabilization phase and then the prescription was switched to MST or TDF for 14 days in the treatment phase. Oral MHIR was provided as rescue medication for breakthrough pain. Assessments of the pain intensity, pain frequency, degree of pain improvement, profile of mood states, quality of sleep, activity status and adverse effects were performed before and after the stabilization phase and before and after the treatment phase. RESULTS: Forty of 47 cancer patients completed the study with 20 patients in each group. There were significant (p < 0.05) improvements in pain intensity, pain frequency, mood states and quality of sleep in both groups before and after treatment, while improvement in the activity status was not significant. No specific adverse effects were encountered except for drowsiness which occurred in 6 patients treated with MST and 5 treated with TDF (p < 0.05). Insomnia was significantly improved (p < 0.05) with both regimens compared with that in the period before treatment. There were no significant differences between the two study groups in analgesic efficacy or adverse effects. CONCLUSIONS: These results suggest that TDF and MSt are safe and effective analgesics for the management of chronic cancer pain. However, TDF provides a simpler and more convenient treatment for those patients with severe nausea, vomiting or dysphagia.


Asunto(s)
Analgésicos Opioides/administración & dosificación , Fentanilo/administración & dosificación , Morfina/administración & dosificación , Neoplasias/fisiopatología , Dolor Intratable/tratamiento farmacológico , Administración Cutánea , Administración Oral , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad
3.
J Infect Dis ; 146(1): 85-90, 1982 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-7045255

RESUMEN

A double-blind, placebo-controlled trial of topical 5% acyclovir (ACV) in polyethylene glycol (PEG) was carried out among 208 patients who had an episode of herpes simplex labialis. Patients who were treated with ACV had a greater decrease in median titers of virus in lesions between the first and second visits to the clinic than did patients who were treated with placebo (-1.5 log pfu [plaque-forming units] vs. -0.2 log pfu; P = 0.04). The antiviral effect occurred in the subgroup of patients who entered the study 0-8 hr after the onset of lesions. No differences were noted in the remaining patients who began treatment 9-25 hr after onset. An examination of the subgroup who had virus-positive specimens before treatment revealed prominent and more statistically significant virologic differences between treatment groups. No clinical benefit from treatment with ACV was observed; however, the present study describes the first antiviral effect of topical treatment for recurrent herpes labialis and identifies treatment strategies for future studies.


Asunto(s)
Antivirales/administración & dosificación , Guanina/análogos & derivados , Herpes Labial/tratamiento farmacológico , Aciclovir , Administración Tópica , Ensayos Clínicos como Asunto , Método Doble Ciego , Guanina/administración & dosificación , Humanos , Placebos , Polietilenglicoles , Recurrencia
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda